'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective

Vox Sanguinis

Volumn 86, Issue 2, 2004, Pages 120-124

  Clark, A D ^a   Gordon, W C ^a   Walker, I D ^a   Tait, R C ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Coagulopathy; Massive blood transfusion; Recombinant FVIIa

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AORTIC RUPTURE; BLOOD BANKS; BLOOD COAGULATION DISORDERS; ERYTHROCYTE TRANSFUSION; FACTOR VII; FEMALE; HEMORRHAGE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; SALVAGE THERAPY; TREATMENT FAILURE; WOUNDS AND INJURIES;

EID: 1842419461     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0042-9007.2004.00393.x     Document Type: Article

References (14)

1. White B, McHale J, Ravi N, Reynolds J, Stephens R, Moriarty J, Smith OP: Successful use of recombinant FVIla (Novoseven) in the management of intractable post-surgical intra-abdominal haemorrhage. Br J Haematol 1999; 107:677-678
2. Svartholm E, Annerhagen V, Lanne T: Treatment of bleeding in severe necrotizing pancreatitis with recombinant factor VIIa. Anesthesiology 2002; 96:1528
3. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, Lynn M: Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51:431-438
4. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M: Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361:201-205
5. Kovesi T, Royston D: Pharmacological approaches to reducing allogeneic blood exposure. Vox Sang 2003; 84:2-10
6. Laffan M, O'Connell N, Perry D, Hodgson A, O'Shaughnessy D, Smith O: Analysis and results of the recombinant factor VIIa extended use registry. Blood Coagul Fibrinol 2003; 14:S35-S38
7. Kenet G, Walden R, Eldad A, Martinowitz U: Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354:1879
8. Stainsby D, MacLennan S, Hamilton PJ: Management of massive blood loss: a template guideline. Br J Anaesth 2000; 85:487-491
9. Hiippala ST, Myllyla GJ, Vahtera EM: Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81:360-365
10. Ciavarella D, Reed RL, Counts RB, Baron L, Pavlin E, Heimbach DM, Carrico CJ: Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol 1987; 67:365-368
11. Contreras M: Consensus conference on platelet transfusion. Final statement. Blood Rev 1998; 12:239-240
12. Harvey MP, Greenfield TP, Sugrue ME, Rosenfeld D: Massive blood transfusion in a tertiary referral hospital. Clinical outcomes and haemostatic complications. Med J Aust 1995; 163:356-369
13. Schulman S: Safety, efficacy and lessons from continuous infusion with rFVIIa, rFVIIa-CI Group. Haemophilia 1998; 4:564-567
14. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U: A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003; 1:450-455